Loading…
The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma
Purpose The human gene PTPN11, which encodes the non-receptor protein tyrosine phosphatase of Src homology phosphotyrosine phosphatase 2 (Shp2), has been previously well interpreted as a proto-oncogene in a variety of malignancies. However, the tumor suppressor role of Shp2 has also been reported. T...
Saved in:
| Published in: | Journal of cancer research and clinical oncology 2012-04, Vol.138 (4), p.637-646 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c433t-c5325eac4f5f5851824405504022f88913d7ef4bf3231271bced167ccfc00abc3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c433t-c5325eac4f5f5851824405504022f88913d7ef4bf3231271bced167ccfc00abc3 |
| container_end_page | 646 |
| container_issue | 4 |
| container_start_page | 637 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 138 |
| creator | Jiang, Chengying Hu, Fangke Tai, Yanhong Du, Jingli Mao, Beibei Yuan, Zengqiang Wang, Yan Wei, Lixin |
| description | Purpose
The human gene PTPN11, which encodes the non-receptor protein tyrosine phosphatase of Src homology phosphotyrosine phosphatase 2 (Shp2), has been previously well interpreted as a proto-oncogene in a variety of malignancies. However, the tumor suppressor role of Shp2 has also been reported. The present study was conducted to investigate the role of Shp2 expression and its associated clinical manifestations in hepatocellular carcinoma (HCC).
Methods
A tissue microarray of 333 pairs of HCC and self-matched adjacent non-tumor tissues was constructed, and the expression of Shp2 was determined by immunohistochemistry. The results were also conformed by Western blotting and quantitative PCR of 31 self-paired fresh HCC specimens. The associations of Shp2 expression with 25 clinicopathologic features were analyzed. Overall survival analysis and multivariate analysis were performed.
Results
Significantly decreased Shp2 expression in tumor tissues (T) compared with adjacent non-tumor tissues (NT) could be detected, and the positive rate was 66.1 and 96.7%, respectively. We combined the T and NT Shp2 immunoreactivity by a variable of the decrease in Shp2 expression (ΔShp2) and divided cases into 2 groups: T |
| doi_str_mv | 10.1007/s00432-011-1143-5 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_928913666</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2609814711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-c5325eac4f5f5851824405504022f88913d7ef4bf3231271bced167ccfc00abc3</originalsourceid><addsrcrecordid>eNp9kU1LxDAQhoMouq7-AC8SBNFLNZOPfhxF_ALBg-u5ZLOJW2mbmmkP--9N2dUFQQMhmeSZN5N5CTkBdgWMZdfImBQ8YQAJgBSJ2iETGE9ACLVLJgwySBSH9IAcIn6wGKuM75MDHkfOhJwQM1ta2g-NDxSHrgsWMW6Dry31jr4GQ5e-8bV_X9Fu6THOfhU8Vq3dxLrXaCmnVUuXttO9N7auh1oHanQwVesbfUT2nK7RHm_WKXm7v5vdPibPLw9PtzfPiZFC9IlRgiurjXTKqVxBzqVkSjHJOHd5XoBYZNbJuRNcAM9gbuwC0swYZxjTcyOm5GKt2wX_OVjsy6bCsRzdWj9gWfBRJE3TSF7-S8bu5rkUacEjevYL_fBDaOM_Rj3GCh47PiWwhkzsDQbryi5UjQ6rqDSKZeXaqjJaVY5WlSrmnG6Eh3ljFz8Z395E4HwDaDS6dkG3psItp1IFhRw_w9ccxqv23YZthX-__gXqo6sh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>928009214</pqid></control><display><type>article</type><title>The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma</title><source>Springer Nature</source><creator>Jiang, Chengying ; Hu, Fangke ; Tai, Yanhong ; Du, Jingli ; Mao, Beibei ; Yuan, Zengqiang ; Wang, Yan ; Wei, Lixin</creator><creatorcontrib>Jiang, Chengying ; Hu, Fangke ; Tai, Yanhong ; Du, Jingli ; Mao, Beibei ; Yuan, Zengqiang ; Wang, Yan ; Wei, Lixin</creatorcontrib><description>Purpose
The human gene PTPN11, which encodes the non-receptor protein tyrosine phosphatase of Src homology phosphotyrosine phosphatase 2 (Shp2), has been previously well interpreted as a proto-oncogene in a variety of malignancies. However, the tumor suppressor role of Shp2 has also been reported. The present study was conducted to investigate the role of Shp2 expression and its associated clinical manifestations in hepatocellular carcinoma (HCC).
Methods
A tissue microarray of 333 pairs of HCC and self-matched adjacent non-tumor tissues was constructed, and the expression of Shp2 was determined by immunohistochemistry. The results were also conformed by Western blotting and quantitative PCR of 31 self-paired fresh HCC specimens. The associations of Shp2 expression with 25 clinicopathologic features were analyzed. Overall survival analysis and multivariate analysis were performed.
Results
Significantly decreased Shp2 expression in tumor tissues (T) compared with adjacent non-tumor tissues (NT) could be detected, and the positive rate was 66.1 and 96.7%, respectively. We combined the T and NT Shp2 immunoreactivity by a variable of the decrease in Shp2 expression (ΔShp2) and divided cases into 2 groups: T < NT and T ≥ NT. Survival analysis showed both low Shp2 expression and T < NT group were significantly associated with short overall survival. Multivariate analysis showed ΔShp2 was an independent prognostic marker (
P
= 0.033; HR: 0.527; 95% CI: 0.293–0.950).
Conclusion
Shp2 is a tumor suppressor, and the decrease in Shp2 expression was a new prognostic marker in HCC. The oncogenic role of Shp2 was tissue specific, and the therapeutic target of human gene PTPN11 should be reconsidered.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-011-1143-5</identifier><identifier>PMID: 22228034</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Blotting, Western ; Cancer ; Cancer Research ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - metabolism ; Carcinoma, Hepatocellular - pathology ; Gastroenterology. Liver. Pancreas. Abdomen ; Gene Expression Regulation, Neoplastic ; Hematology ; Hepatocellular carcinoma ; Homology ; Humans ; Immunohistochemistry ; Internal Medicine ; Kaplan-Meier Estimate ; Liver Neoplasms - genetics ; Liver Neoplasms - metabolism ; Liver Neoplasms - pathology ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Malignancy ; Medical sciences ; Medicine ; Medicine & Public Health ; Microarray Analysis - statistics & numerical data ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Oncology ; Original Article ; Pharmacology. Drug treatments ; Phosphorus content ; Polymerase chain reaction ; Prognosis ; Proportional Hazards Models ; Protein Tyrosine Phosphatase, Non-Receptor Type 11 - genetics ; Protein Tyrosine Phosphatase, Non-Receptor Type 11 - metabolism ; Protein-tyrosine-phosphatase ; Proto-oncogenes ; Reverse Transcriptase Polymerase Chain Reaction ; Src protein ; Survival ; Tumor suppressor genes ; Tumor Suppressor Proteins - genetics ; Tumor Suppressor Proteins - metabolism ; Tumors ; Western blotting</subject><ispartof>Journal of cancer research and clinical oncology, 2012-04, Vol.138 (4), p.637-646</ispartof><rights>Springer-Verlag 2012</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-c5325eac4f5f5851824405504022f88913d7ef4bf3231271bced167ccfc00abc3</citedby><cites>FETCH-LOGICAL-c433t-c5325eac4f5f5851824405504022f88913d7ef4bf3231271bced167ccfc00abc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25651946$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22228034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiang, Chengying</creatorcontrib><creatorcontrib>Hu, Fangke</creatorcontrib><creatorcontrib>Tai, Yanhong</creatorcontrib><creatorcontrib>Du, Jingli</creatorcontrib><creatorcontrib>Mao, Beibei</creatorcontrib><creatorcontrib>Yuan, Zengqiang</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Wei, Lixin</creatorcontrib><title>The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
The human gene PTPN11, which encodes the non-receptor protein tyrosine phosphatase of Src homology phosphotyrosine phosphatase 2 (Shp2), has been previously well interpreted as a proto-oncogene in a variety of malignancies. However, the tumor suppressor role of Shp2 has also been reported. The present study was conducted to investigate the role of Shp2 expression and its associated clinical manifestations in hepatocellular carcinoma (HCC).
Methods
A tissue microarray of 333 pairs of HCC and self-matched adjacent non-tumor tissues was constructed, and the expression of Shp2 was determined by immunohistochemistry. The results were also conformed by Western blotting and quantitative PCR of 31 self-paired fresh HCC specimens. The associations of Shp2 expression with 25 clinicopathologic features were analyzed. Overall survival analysis and multivariate analysis were performed.
Results
Significantly decreased Shp2 expression in tumor tissues (T) compared with adjacent non-tumor tissues (NT) could be detected, and the positive rate was 66.1 and 96.7%, respectively. We combined the T and NT Shp2 immunoreactivity by a variable of the decrease in Shp2 expression (ΔShp2) and divided cases into 2 groups: T < NT and T ≥ NT. Survival analysis showed both low Shp2 expression and T < NT group were significantly associated with short overall survival. Multivariate analysis showed ΔShp2 was an independent prognostic marker (
P
= 0.033; HR: 0.527; 95% CI: 0.293–0.950).
Conclusion
Shp2 is a tumor suppressor, and the decrease in Shp2 expression was a new prognostic marker in HCC. The oncogenic role of Shp2 was tissue specific, and the therapeutic target of human gene PTPN11 should be reconsidered.</description><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Blotting, Western</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - metabolism</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hematology</subject><subject>Hepatocellular carcinoma</subject><subject>Homology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Internal Medicine</subject><subject>Kaplan-Meier Estimate</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - metabolism</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Malignancy</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Microarray Analysis - statistics & numerical data</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphorus content</subject><subject>Polymerase chain reaction</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Protein Tyrosine Phosphatase, Non-Receptor Type 11 - genetics</subject><subject>Protein Tyrosine Phosphatase, Non-Receptor Type 11 - metabolism</subject><subject>Protein-tyrosine-phosphatase</subject><subject>Proto-oncogenes</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Src protein</subject><subject>Survival</subject><subject>Tumor suppressor genes</subject><subject>Tumor Suppressor Proteins - genetics</subject><subject>Tumor Suppressor Proteins - metabolism</subject><subject>Tumors</subject><subject>Western blotting</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kU1LxDAQhoMouq7-AC8SBNFLNZOPfhxF_ALBg-u5ZLOJW2mbmmkP--9N2dUFQQMhmeSZN5N5CTkBdgWMZdfImBQ8YQAJgBSJ2iETGE9ACLVLJgwySBSH9IAcIn6wGKuM75MDHkfOhJwQM1ta2g-NDxSHrgsWMW6Dry31jr4GQ5e-8bV_X9Fu6THOfhU8Vq3dxLrXaCmnVUuXttO9N7auh1oHanQwVesbfUT2nK7RHm_WKXm7v5vdPibPLw9PtzfPiZFC9IlRgiurjXTKqVxBzqVkSjHJOHd5XoBYZNbJuRNcAM9gbuwC0swYZxjTcyOm5GKt2wX_OVjsy6bCsRzdWj9gWfBRJE3TSF7-S8bu5rkUacEjevYL_fBDaOM_Rj3GCh47PiWwhkzsDQbryi5UjQ6rqDSKZeXaqjJaVY5WlSrmnG6Eh3ljFz8Z395E4HwDaDS6dkG3psItp1IFhRw_w9ccxqv23YZthX-__gXqo6sh</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>Jiang, Chengying</creator><creator>Hu, Fangke</creator><creator>Tai, Yanhong</creator><creator>Du, Jingli</creator><creator>Mao, Beibei</creator><creator>Yuan, Zengqiang</creator><creator>Wang, Yan</creator><creator>Wei, Lixin</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20120401</creationdate><title>The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma</title><author>Jiang, Chengying ; Hu, Fangke ; Tai, Yanhong ; Du, Jingli ; Mao, Beibei ; Yuan, Zengqiang ; Wang, Yan ; Wei, Lixin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-c5325eac4f5f5851824405504022f88913d7ef4bf3231271bced167ccfc00abc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Blotting, Western</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - metabolism</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hematology</topic><topic>Hepatocellular carcinoma</topic><topic>Homology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Internal Medicine</topic><topic>Kaplan-Meier Estimate</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - metabolism</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Malignancy</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Microarray Analysis - statistics & numerical data</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphorus content</topic><topic>Polymerase chain reaction</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Protein Tyrosine Phosphatase, Non-Receptor Type 11 - genetics</topic><topic>Protein Tyrosine Phosphatase, Non-Receptor Type 11 - metabolism</topic><topic>Protein-tyrosine-phosphatase</topic><topic>Proto-oncogenes</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Src protein</topic><topic>Survival</topic><topic>Tumor suppressor genes</topic><topic>Tumor Suppressor Proteins - genetics</topic><topic>Tumor Suppressor Proteins - metabolism</topic><topic>Tumors</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Chengying</creatorcontrib><creatorcontrib>Hu, Fangke</creatorcontrib><creatorcontrib>Tai, Yanhong</creatorcontrib><creatorcontrib>Du, Jingli</creatorcontrib><creatorcontrib>Mao, Beibei</creatorcontrib><creatorcontrib>Yuan, Zengqiang</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Wei, Lixin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Chengying</au><au>Hu, Fangke</au><au>Tai, Yanhong</au><au>Du, Jingli</au><au>Mao, Beibei</au><au>Yuan, Zengqiang</au><au>Wang, Yan</au><au>Wei, Lixin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2012-04-01</date><risdate>2012</risdate><volume>138</volume><issue>4</issue><spage>637</spage><epage>646</epage><pages>637-646</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>Purpose
The human gene PTPN11, which encodes the non-receptor protein tyrosine phosphatase of Src homology phosphotyrosine phosphatase 2 (Shp2), has been previously well interpreted as a proto-oncogene in a variety of malignancies. However, the tumor suppressor role of Shp2 has also been reported. The present study was conducted to investigate the role of Shp2 expression and its associated clinical manifestations in hepatocellular carcinoma (HCC).
Methods
A tissue microarray of 333 pairs of HCC and self-matched adjacent non-tumor tissues was constructed, and the expression of Shp2 was determined by immunohistochemistry. The results were also conformed by Western blotting and quantitative PCR of 31 self-paired fresh HCC specimens. The associations of Shp2 expression with 25 clinicopathologic features were analyzed. Overall survival analysis and multivariate analysis were performed.
Results
Significantly decreased Shp2 expression in tumor tissues (T) compared with adjacent non-tumor tissues (NT) could be detected, and the positive rate was 66.1 and 96.7%, respectively. We combined the T and NT Shp2 immunoreactivity by a variable of the decrease in Shp2 expression (ΔShp2) and divided cases into 2 groups: T < NT and T ≥ NT. Survival analysis showed both low Shp2 expression and T < NT group were significantly associated with short overall survival. Multivariate analysis showed ΔShp2 was an independent prognostic marker (
P
= 0.033; HR: 0.527; 95% CI: 0.293–0.950).
Conclusion
Shp2 is a tumor suppressor, and the decrease in Shp2 expression was a new prognostic marker in HCC. The oncogenic role of Shp2 was tissue specific, and the therapeutic target of human gene PTPN11 should be reconsidered.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>22228034</pmid><doi>10.1007/s00432-011-1143-5</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2012-04, Vol.138 (4), p.637-646 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_928913666 |
| source | Springer Nature |
| subjects | Adult Antineoplastic agents Biological and medical sciences Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Blotting, Western Cancer Cancer Research Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - pathology Gastroenterology. Liver. Pancreas. Abdomen Gene Expression Regulation, Neoplastic Hematology Hepatocellular carcinoma Homology Humans Immunohistochemistry Internal Medicine Kaplan-Meier Estimate Liver Neoplasms - genetics Liver Neoplasms - metabolism Liver Neoplasms - pathology Liver. Biliary tract. Portal circulation. Exocrine pancreas Malignancy Medical sciences Medicine Medicine & Public Health Microarray Analysis - statistics & numerical data Middle Aged Multivariate Analysis Neoplasm Staging Oncology Original Article Pharmacology. Drug treatments Phosphorus content Polymerase chain reaction Prognosis Proportional Hazards Models Protein Tyrosine Phosphatase, Non-Receptor Type 11 - genetics Protein Tyrosine Phosphatase, Non-Receptor Type 11 - metabolism Protein-tyrosine-phosphatase Proto-oncogenes Reverse Transcriptase Polymerase Chain Reaction Src protein Survival Tumor suppressor genes Tumor Suppressor Proteins - genetics Tumor Suppressor Proteins - metabolism Tumors Western blotting |
| title | The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T22%3A40%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20tumor%20suppressor%20role%20of%20Src%20homology%20phosphotyrosine%20phosphatase%202%20in%20hepatocellular%20carcinoma&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Jiang,%20Chengying&rft.date=2012-04-01&rft.volume=138&rft.issue=4&rft.spage=637&rft.epage=646&rft.pages=637-646&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/s00432-011-1143-5&rft_dat=%3Cproquest_cross%3E2609814711%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c433t-c5325eac4f5f5851824405504022f88913d7ef4bf3231271bced167ccfc00abc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=928009214&rft_id=info:pmid/22228034&rfr_iscdi=true |